Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Operating Leases (2022 - 2025)

Historic Operating Leases for Cytek Biosciences (CTKB) over the last 4 years, with Q3 2025 value amounting to $16.6 million.

  • Cytek Biosciences' Operating Leases rose 4697.39% to $16.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.6 million, marking a year-over-year increase of 4697.39%. This contributed to the annual value of $11.3 million for FY2024, which is 515.81% down from last year.
  • Cytek Biosciences' Operating Leases amounted to $16.6 million in Q3 2025, which was up 4697.39% from $17.4 million recorded in Q2 2025.
  • Over the past 5 years, Cytek Biosciences' Operating Leases peaked at $17.4 million during Q2 2025, and registered a low of $10.5 million during Q2 2024.
  • For the 4-year period, Cytek Biosciences' Operating Leases averaged around $12.7 million, with its median value being $11.9 million (2023).
  • In the last 5 years, Cytek Biosciences' Operating Leases plummeted by 2178.05% in 2023 and then surged by 6581.75% in 2025.
  • Cytek Biosciences' Operating Leases (Quarter) stood at $15.2 million in 2022, then fell by 21.78% to $11.9 million in 2023, then dropped by 5.16% to $11.3 million in 2024, then surged by 46.67% to $16.6 million in 2025.
  • Its Operating Leases stands at $16.6 million for Q3 2025, versus $17.4 million for Q2 2025 and $11.0 million for Q1 2025.